Difference between revisions of "IDRPublicationList"
From Clinfowiki
| (7 intermediate revisions by one user not shown) | |||
| Line 2: | Line 2: | ||
== True positive == | == True positive == | ||
| − | * ROSIGLITAZONE and claims study - Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation. | + | * '''ROSIGLITAZONE and claims study''' SUMMARY: A claims analysis indicated increased risk of MI, stroke and health failure. This finding triggered trials meta-analysis that confirmed it. This lead to removing the drug from market. Without the IDR, we would still use that drug today. |
| − | ** Graham DJ et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA doi:10.1001/jama.2010.920 http://www.ncbi.nlm.nih.gov/pubmed/20584880 | + | ** ABSTRACT EXTRACT: Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation. |
| + | ** REFERENCE:Graham DJ et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA doi:10.1001/jama.2010.920 http://www.ncbi.nlm.nih.gov/pubmed/20584880 | ||
**** http://en.wikipedia.org/wiki/Rosiglitazone | **** http://en.wikipedia.org/wiki/Rosiglitazone | ||
| + | ** Brownstein, J.S.; Murphy, S.N.; Goldfine, A.B.; Grant, R.W.; Sordo, M.; Gainer, V.; Colecchi, J.A.;Dubey, A.; Nathan, D.M.; Glaser, J.P.; Kohane, I.S. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care, vol 33, no. 3; 2010 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827502 | ||
| + | ** http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf | ||
| − | * CIMETIDINE and drug repurposing | + | * '''CIMETIDINE and drug repurposing''' SUMMARY: Database finding revealed possible second use of a drug. This database finding lead to a mouse model experiment(confirmed effect) (clinical trial started [documentation missing]. Without the IDR/database, we would never discover the additional therapeutic effect. |
| − | ** cimetidine and lung cancer http://www.ncbi.nlm.nih.gov/pubmed/21849665 | + | ** ABSTRACT EXTRACT:Here, we present a systematic computational approach to predict novel therapeutic indications on the basis of comprehensive testing of molecular signatures in drug-disease pairs. We integrated gene expression measurements from 100 diseases and gene expression measurements on 164 drug compounds, yielding predicted therapeutic potentials for these drugs. We recovered many known drug and disease relationships using computationally derived therapeutic potentials and also predict many new indications for these 164 drugs. We experimentally validated a prediction for the antiulcer drug cimetidine as a candidate therapeutic in the treatment of lung adenocarcinoma, and demonstrate its efficacy both in vitro and in vivo using mouse xenograft models |
| + | |||
| + | ** REFERENCE:cimetidine and lung cancer http://www.ncbi.nlm.nih.gov/pubmed/21849665 | ||
| + | |||
| + | |||
| + | * replicate a single genetic study (GWAS) (RA) | ||
| + | ** http://www.ncbi.nlm.nih.gov/pubmed/21211616 | ||
| + | |||
| + | |||
| + | * replicate a group of GWAS findings | ||
| + | ** http://www.ncbi.nlm.nih.gov/pubmed/20362271 | ||
| + | |||
| + | * thanks to an IDR, we were able to complete this trial (anecdotal, no PMID available) | ||
== False positive == | == False positive == | ||
| + | Example of a published findings in an IDR that later turned out to be false. E.g., reporting an effect of a drug (or other findings) from an IDR analysis, but later human trials or other experiments did not validate it. | ||
| + | * tbd | ||
| + | |||
| + | == Other bibliographies == | ||
| + | * UK's CPRD (Clinical Practice Research Datalink) | ||
| + | http://www.cprd.com/Bibliography/Researchpapers.asp | ||
| + | |||
| + | == See Also == | ||
| + | * [[CIDR]] | ||
Latest revision as of 18:59, 2 August 2013
List of publications that report use of an Integrated Data Repository (IDR). ("IDR success stories")
True positive
- ROSIGLITAZONE and claims study SUMMARY: A claims analysis indicated increased risk of MI, stroke and health failure. This finding triggered trials meta-analysis that confirmed it. This lead to removing the drug from market. Without the IDR, we would still use that drug today.
- ABSTRACT EXTRACT: Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation.
- REFERENCE:Graham DJ et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA doi:10.1001/jama.2010.920 http://www.ncbi.nlm.nih.gov/pubmed/20584880
- Brownstein, J.S.; Murphy, S.N.; Goldfine, A.B.; Grant, R.W.; Sordo, M.; Gainer, V.; Colecchi, J.A.;Dubey, A.; Nathan, D.M.; Glaser, J.P.; Kohane, I.S. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care, vol 33, no. 3; 2010 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827502
- http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218493.pdf
- CIMETIDINE and drug repurposing SUMMARY: Database finding revealed possible second use of a drug. This database finding lead to a mouse model experiment(confirmed effect) (clinical trial started [documentation missing]. Without the IDR/database, we would never discover the additional therapeutic effect.
- ABSTRACT EXTRACT:Here, we present a systematic computational approach to predict novel therapeutic indications on the basis of comprehensive testing of molecular signatures in drug-disease pairs. We integrated gene expression measurements from 100 diseases and gene expression measurements on 164 drug compounds, yielding predicted therapeutic potentials for these drugs. We recovered many known drug and disease relationships using computationally derived therapeutic potentials and also predict many new indications for these 164 drugs. We experimentally validated a prediction for the antiulcer drug cimetidine as a candidate therapeutic in the treatment of lung adenocarcinoma, and demonstrate its efficacy both in vitro and in vivo using mouse xenograft models
- REFERENCE:cimetidine and lung cancer http://www.ncbi.nlm.nih.gov/pubmed/21849665
- replicate a single genetic study (GWAS) (RA)
- replicate a group of GWAS findings
- thanks to an IDR, we were able to complete this trial (anecdotal, no PMID available)
False positive
Example of a published findings in an IDR that later turned out to be false. E.g., reporting an effect of a drug (or other findings) from an IDR analysis, but later human trials or other experiments did not validate it.
- tbd
Other bibliographies
- UK's CPRD (Clinical Practice Research Datalink)
http://www.cprd.com/Bibliography/Researchpapers.asp
